[ Pobierz całość w formacie PDF ]
ligand regulates the proliferation of mammary epithelial cells
development and function. Nat Rev Genet 2003, 4:638-649.
5. Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R: via Id2. Mol Cell Biol 2006, 26:1002-1013.
Daily and cyclic parathyroid hormone in women receiving 23. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K,
alendronate. N Engl J Med 2005, 353:566-575. Yokochi T, Oda H, Nakamura K, Ida N, et al.: RANKL maintains
6. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, bone homeostasis through c-Fos-dependent induction of
Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ; PaTH interferon-beta. Nature 2002, 416:744-749.
Study Investigators: The effects of parathyroid hormone and 24. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K,
alendronate alone or in combination in postmenopausal Takaoka A, Yokochi T, Oda H, Tanaka K, et al.: T-cell-mediated
osteoporosis. N Engl J Med 2003, 349:1207-1215. regulation of osteoclastogenesis by signalling cross-talk
7. Ma YL, Bryant HU, Zeng Q, Schmidt A, Hoover J, Cole HW, Yao between RANKL and IFN-gamma. Nature 2000, 408:600-605.
W, Jee WS, Sato M: New bone formation with teriparatide 25. Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA:
[human parathyroid hormone-(1-34)] is not retarded by long- Expression of RANKL/RANK/OPG in primary and metastatic
term pretreatment with alendronate, estrogen, or raloxifene in human prostate cancer as markers of disease stage and
ovariectomized rats. Endocrinology 2003, 144:2008-2015. functional regulation. Cancer 2006, 107:289-298.
8. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy 26. Kapur RP, Yao Z, Iida MH, Clarke CM, Doggett B, Xing L, Boyce
R, Nguyen HQ, Wooden S, Bennett L, Boone T, et al.: Osteopro- BF: Malignant autosomal recessive osteopetrosis caused by
tegerin: a novel secreted protein involved in the regulation of spontaneous mutation of murine Rank. J Bone Miner Res
bone density. Cell 1997, 89:309-319. 2004, 19:1689-1697.
9. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, 27. Hughes AE, Ralston SH, Marken J, Bell C, MacPherson H,
Sato Y, Goto M, Yamaguchi K, Kuriyama M, et al.: Identity of Wallace RG, van Hul W, Whyte MP, Nakatsuka K, Hovy L, et al.:
osteoclastogenesis inhibitory factor (OCIF) and osteoprote- Mutations in TNFRSF11A, affecting the signal peptide of
gerin (OPG): a mechanism by which OPG/OCIF inhibits osteo- RANK, cause familial expansile osteolysis. Nat Genet 2000,
clastogenesis in vitro. Endocrinology 1998, 139:1329-1337. 24:45-48.
10. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, 28. Hofbauer LC, Schoppet M: Clinical implications of the osteo-
Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, et al.: protegerin/RANKL/RANK system for bone and vascular dis-
Osteoclast differentiation factor is a ligand for osteoprote- eases. JAMA 2004, 292:490-495.
gerin/osteoclastogenesis-inhibitory factor and is identical to 29. Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN,
TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95:3597-3602. McAlister WH, Mumm S: Osteoprotegerin deficiency and juve-
11. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, nile Paget s disease. N Engl J Med 2002, 347:175-184.
Elliott R, Colombero A, Elliott G, Scully S, et al.: Osteoprotegerin 30. Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, Mulley
ligand is a cytokine that regulates osteoclast differentiation J, Love DR, Seidel J, Fawkner M, et al.: A mutation in the gene
and activation. Cell 1998, 93:165-176. TNFRSF11B encoding osteoprotegerin causes an idiopathic
12. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, hyperphosphatasia phenotype. Hum Mol Genet 2002, 11:
Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Gal- 2119-2127.
ibert L: A homologue of the TNF receptor and its ligand 31. Boyce BF, Xing L, Chen D: Osteoprotegerin, the bone protec-
enhance T-cell growth and dendritic-cell function. Nature tor, is a surprising target for beta-catenin signaling. Cell
1997, 390:175-179. Metab 2005, 2:344-345.
Page 6 of 7
(page number not for citation purposes)
Available online http://arthritis-research.com/content/9/S1/S1
32. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C,
Scully S, Tan HL, Xu W, Lacey DL, et al.: Osteoprotegerin-defi-
cient mice develop early onset osteoporosis and arterial calci-
fication. Genes Dev 1998, 12:1260-1268.
33. Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M,
Schwartz SM, Giachelli CM, Rosenfeld ME: Osteoprotegerin
inactivation accelerates advanced atherosclerotic lesion pro-
gression and calcification in older ApoE-/- mice. Arterioscler
Thromb Vasc Biol 2006, 26:2117-2124.
34. Collin-Osdoby P: Regulation of vascular calcification by osteo-
clast regulatory factors RANKL and osteoprotegerin. Circ Res
2004, 95:1046-1057.
35. Rogers A, Eastell R: Circulating osteoprotegerin and receptor
activator for nuclear factor kappaB ligand: clinical utility in
metabolic bone disease assessment. J Clin Endocrinol Metab
2005, 90:6323-6331.
36. Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A,
Morony S, Capparelli C, Van G, Kaufman S, et al.: TRAF6 defi-
ciency results in osteopetrosis and defective interleukin-1,
CD40, and LPS signaling. Genes Dev 1999, 13:1015-1024.
37. Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K,
Nakao K, Nakamura K, Katsuki M, Yamamoto T, et al.: Severe
osteopetrosis, defective interleukin-1 signalling and lymph
node organogenesis in TRAF6-deficient mice. Genes Cells
1999, 4:353-362.
38. Wada T, Nakashima T, Oliveira-dos-Santos AJ, Gasser J, Hara H,
Schett G, Penninger JM: The molecular scaffold Gab2 is a
crucial component of RANK signaling and osteoclasto-
genesis. Nat Med 2005, 11:394-399.
39. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H,
Saiura A, Isobe M, Yokochi T, Inoue J, et al.: Induction and acti-
vation of the transcription factor NFATc1 (NFAT2) integrate
RANKL signaling in terminal differentiation of osteoclasts. Dev
Cell 2002, 3:889-901.
40. Yao Z, Matsuo K, Nishimura R, Xing L, Boyce BF: c-Fos/NFAT1-
or 2-mediated osteoclastogenesis requires NF-kB p50/p52
expression. J Bone Miner Res 2005, Suppl 1:S145.
41. Thiebaud D, Krieg MA, Gillard-Berguer D, Jacquet AF, Goy JJ,
Burckhardt P: Cyclosporine induces high bone turnover and
may contribute to bone loss after heart transplantation. Eur J
Clin Invest 1996, 26:549-555.
42. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer
RR, de Crombrugghe B: The novel zinc finger-containing tran-
scription factor osterix is required for osteoblast differentia-
tion and bone formation. Cell 2002, 108:17-29.
43. Koga T, Matsui Y, Asagiri M, Kodama T, de Crombrugghe B,
Nakashima K, Takayanagi H: NFAT and Osterix cooperatively
regulate bone formation. Nat Med 2005, 11:880-885.
44. Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, Iwata T,
Ohnishi H, Matozaki T, Kodama T, et al.: Costimulatory signals
mediated by the ITAM motif cooperate with RANKL for bone
homeostasis. Nature 2004, 428:758-763.
45. Takayanagi H: Mechanistic insight into osteoclast differentia-
tion in osteoimmunology. J Mol Med 2005, 83:170-179.
46. Yao Z, Li P, Zhang Q, Schwarz EM, Keng P, Arbini A, Boyce BF,
±
Xing L: Tumor necrosis factor-± increases circulating osteo-
clast precursor numbers by promoting their proliferation and
differentiation in the bone marrow through up-regulation of c-
Fms expression. J Biol Chem 2006, 281:11846-11855.
Page 7 of 7
(page number not for citation purposes)
[ Pobierz całość w formacie PDF ]